Source comparison
PT-141 News 2026: Clinical Research Applications Comparison
PT-141 research in 2026 spans multiple application areas, each with distinct protocols and outcome measures. The table below compares current research focus areas, typical dosing ranges, and assessment methods used in published studies. Melanocortin receptor p
This comparison does not assign a generated winner or score.
- PT-141 research in 2026 spans multiple application areas, each with distinct protocols and outcome measures. The table below compares current research focus areas, typical dosing ranges, and assessment methods used in published studies.
- Melanocortin receptor pathway mapping
- 0.5–2.0mg (rodent models, scaled)
- Receptor occupancy via PET imaging, cAMP assay, gene expression
- 4–12 weeks
- MC3R activation shown equally critical as MC4R in CNS arousal pathways
- Gold standard for mechanistic research; requires advanced imaging
- Female hypoactive sexual desire disorder (HSDD)
- 1.75mg per administration
- Female Sexual Function Index (FSFI), distress scales
- 12–24 weeks
- No major new efficacy data in 2026; focus shifted to long-term safety
- Established application with FDA approval (Vyleesi); research focus on adherence
- Male erectile function (off-label research)
- 1.0–2.0mg per administration
- International Index of Erectile Function (IIEF), patient-reported outcomes
- 8–16 weeks
- Mixed results; PT-141 shows benefit in psychogenic ED, minimal effect in vascular ED
- Not a first-line research focus; PDE5 inhibitors remain more effective for vascular ED
- Energy homeostasis and metabolic signaling
- 0.5–1.5mg daily or alternate-day
- Body weight, food intake, glucose tolerance test, insulin sensitivity
- 8–20 weeks
- MC3R knockout models showed 40% reduced metabolic response to PT-141
- Emerging area; MC3R's role in metabolism may expand PT-141 research applications
- Neurotransmitter modulation studies
- 0.5–1.0mg single dose or repeated
- Dopamine/norepinephrine levels via microdialysis, behavioral assays
- 1–8 weeks
- PT-141 elevates dopamine in nucleus accumbens 30–50% above baseline within 60 minutes
- Valuable for understanding reward and motivation pathways; overlaps with addiction research